Lot documentation is pending
We show no result for this exact configuration while its lot-specific report is unavailable.
Browse the COA library
Purity:99.38% by HPLC
In stock 
Package image for the selected configuration.
C-AMYLIN / G1-S 5 mg + 5 mg
A two-component C-AMYLIN / G1-S research peptide blend containing 5 mg + 5 mg.
Available to verified research accountsExact-SKU documentationLaboratory research use only
The U.S. Food and Drug Administration has not evaluated statements on this site. Stack Research products are not intended to diagnose, treat, cure, or prevent any disease or medical condition.
Lab results for the selected configuration
The published laboratory report covers this exact lot.
- Exact SKU
- STK-CS10
- Lot
- 1040
- Laboratory
- Accumark Labs
- Report ID
- CPBH-2824
- Sample received
- 2026-03-02
- Published
- July 29, 2026
IdentityConforms
HPLC purity99.38% by HPLC
Measured content10.76 mg measured
Bacterial endotoxin
Sterility
Read the complete laboratory report
Open full report
Open the PDF to read every page in the lot-specific report.
Documentation is pending for this exact SKU
We show no purity, identity, content, or contaminant result until a lot-specific report is available.
About C-AMYLIN / G1-S
The linked clinical papers discuss cagrilintide, a long-acting amylin analogue, together with semaglutide, a GLP-1 receptor agonist. Their study products and administration designs are separate from this fixed 5 mg + 5 mg catalog configuration.
The cited papers discuss named components, not this combined Stack Research formulation. They do not establish the blend's identity, component interaction, stability, purity, performance, or suitability. For lawful in-vitro laboratory or analytical research only. Not for human or veterinary use.
Configuration and documentation
The configuration selected above controls the exact SKU, package image, and lot report shown on this page.
Research-use boundary
This page does not provide dosing, administration, treatment, diagnostic, or human-outcome guidance.
Product specifications
- Available configurations
- 5 mg + 5 mg
- Physical form
- Research blend
- Composition
- C-AMYLIN / G1-S two-component peptide blend
- Documentation
- Lot-specific COA published for this exact SKU.
Research & literature
Researchers studied the two named compounds together in the publications below. Only the lot report above evaluates the Stack Research blend.
A paper's findings do not establish the identity, purity, safety, or intended use of this product.
Search PubMed for C-AMYLIN / G1-S (opens in a new tab)- Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Enebo LB et al. · The Lancet · 2021 PMID: 33894838 (opens in a new tab)
- Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Frias JP et al. · The Lancet · 2023 PMID: 37364590 (opens in a new tab)
Mechanism & research background
The selected clinical papers study cagrilintide, a long-acting amylin analogue, together with semaglutide, a GLP-1 receptor agonist. Those study products and administration designs are separate from this fixed Stack Research configuration.
Researchers studied the two named compounds together in the publications below. Only the lot report above evaluates the Stack Research blend.
Researchers should read each linked paper for its model, methods, and limits. The cited literature does not supply instructions for this product.
Frequently asked questions
What are the two literature topics for this blend?
The linked papers study cagrilintide, an amylin analogue, with semaglutide, a GLP-1 receptor agonist. The studies use their own materials and protocols.
Do those studies verify the fixed 5 mg + 5 mg blend?
No. They do not establish this formulation's identity, component ratio, interaction, stability, purity, or suitability.
Is a lot report available for the selected configuration?
A current lot report covers exact SKU STK-CS10, lot 1040, from Accumark Labs.
Does the selected configuration control the report shown?
Yes. Choosing a configuration updates every SKU-specific field and its linked lot report as one set.
Do the cited papers verify this vial?
No. The papers describe independent research. The lab-results section above contains the lot-specific evidence for this Stack Research product.
Do the studies cover the full C-AMYLIN / G1-S formulation?
Researchers studied the two named compounds together in the publications below. Only the lot report above evaluates the Stack Research blend.
Can this page guide human or veterinary use?
No. Stack Research supplies this product for laboratory research only. This page provides no dosing, administration, treatment, or diagnostic guidance.
Can researchers open the original sources?
Yes. Each citation opens its PubMed record. The search link above opens the complete product-specific query.
More to explore
Browse other products currently listed in the Stack Research catalog.
BPC-157 / TB-500
Research peptide blends · 5 mg + 5 mg / 10 mg + 10 mg View product
CJC-1295 no DAC / Ipamorelin
Research peptide blends · 5 mg + 5 mg View product
GLOW 70
Research peptide blends · 70 mg total View product
KLOW
Research peptide blends · 80 mg total View product
GLP-1 (SE)
Research peptides · 5 mg / 10 mg View product
GLP-2 (TZ)
Research peptides · 10 mg / 30 mg View product
GLP-3 (RT)
Research peptides · 10 mg / 30 mg View product
BPC-157
Research peptides · 5 mg / 10 mg View product
Need documentation for C-AMYLIN / G1-S?
Send the exact SKU and lot so support can trace the applicable product record.